Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Pluvicto × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 39 Metastatic Castration-resistant Prostate Cancer 5 Prostatic Diseases 3 Kidney Neoplasms 3 Urogenital Neoplasms 2 Neoplasms by Site 2 Neoplasms 2 Genital Neoplasms, Male 2 Carcinoma, Renal Cell 2 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer Metastatic 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Male Urogenital Diseases 1 Genital Diseases, Male 1 Disease 1 Clear-cell metastatic renal cell carcinoma 1

Interventions

enzalutamide 7 Prednisone 7 cabazitaxel 6 Radiosurgery 6 Docetaxel 5 Androgen Antagonists 4 Abiraterone Acetate 4 XRP6258 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 pembrolizumab 1 olaparib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 darolutamide 1 apalutamide 1 Zuclomiphene 1 Standard of Care 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisolone 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 LY3023414 1 Injections 1 Hydrocortisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡